Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma fibroblast growthfactor-21 (FGF21) responses to acute alcohol exposure will be evaluated in three groups: A: 15 individuals diagnosed with alcohol dependence (ICD10 code F10.2) and no alcoholic liver diseases, B: 15 healthy individuals with one or two parents with alcohol dependence, and C: 15 healthy matched controls without history of or disposition to alcohol dependence. The experimental day consists of a load of 0.5 g ethanol per kg body weight ingested from time 0-10 minutes followed by a 7 h period in which blood will be sampled with frequent intervals, rating of preference for ethanol, salt, sour, bitterly and sweets, sensations of hunger, appetite, satiety, headache, and nausea will be evaluated using visuel analogue scale and resting energy expenditure will be evaluated using indirect calorimetry.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Alcohol | Experimental | The participant receive 0.5 g ethanol per kg body weight over 10 minutes. Subsequently blood samples are taken frequently the next ten hours. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ethanol | Other | Ethanol administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Fibroblast growthfactor-21 | Plasma FGF21 concentrations, a member of the endocrine FGF-family | One year |
| Measure | Description | Time Frame |
|---|---|---|
| Ethanol | Plasma ethanol concentration | One year |
| Glucose | Plasma glucose concentrations | One year |
Not provided
Inclusion Criteria:
Participants with a father diagnosed with alcohol dependence (group B):
Healthy participants (group C):
Exclusion Criteria:
Participants with a father diagnosed with alcohol dependence (group B):
- Former alcohol dependence or abuse
Healthy participants (group C):
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Filip K Knop, MD | Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for Clinical Metabolic Research, Gentofte Hospital | Hellerup | 2900 | Denmark |
Not provided
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000431 | Ethanol |
| ID | Term |
|---|---|
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
Not provided
Not provided
Three matched groups. Group A: participants diagnosed with alcohol dependence, group B: participants with a father diagnosed with alcohol dependence, and C: a healthy control group.
Not provided
Not provided
Not provided
Not provided
| Insulin and C-peptide | Serum insulin and C-peptide concentrations | One year |
| Glucagon | Plasma glucagon concentration | One year |
| Tumor Necrosis Factor-alpha (TNF) | Plasma TNF-alpha concentrations | One year |
| Lipopolysaccharide Binding Protein (LBP) | Plasma LBP concentrations | One year |
| Interferon-gamma (INF) | Plasma INF-gamma concentrations | One year |
| Interleukine-10 (IL-10) | Plasma IL-10 concentrations | One year |
| Interleukine-8 (IL-8) | Plasma IL-8 concentrations | One year |
| Interleukine-6 (IL-6) | Plasma IL-6 concentrations | One year |